Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research & Development In Brief

This article was originally published in The Tan Sheet

Executive Summary

UC-II more effective than glucosamine plus chondroitin: Undernatured type II collagen, an emerging novel nutraceutical, more effectively eases osteoarthritis pain than glucosamine plus chondroitin, according to a study in the October issue of Internal Journal of Medical Sciences. The study, conducted by researchers including Siba Raychaudhuri at the University of California, Davis, compared the effectiveness of 40 mg UC-II daily to 1,500 mg glucosamine plus 1,200 mg chondroitin daily for three months in 52 people with moderate to severe osteoarthritis. They found UC-II improved subjects' physical function and reduced stiffness and pain 19 percentage points more that glucosamine plus chondroitin, according to the Western Ontario McMaster Osteoarthritis index. Researchers observed similar results with other pain measurement tools. In addition, the study says, people who took UC-II suffered 35 adverse events compared to 58 adverse events related to the glucosamine plus chondroitin supplements

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts